Maxim raised the firm’s price target on Lexaria Bioscience to $12 from $3 and keeps a Buy rating on the shares. Shares have risen sharply over the last several weeks due to a combination of internal and external factors related to activity in the obesity space with GLP-1s and dual agonists, the analyst tells investors in a research note. Lexaria has multiple early stage obesity-focused programs coming up with data events emerging over the next 6-12 months, and this is now factored into the firm’s model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LEXX:
- Lexaria Advances Drug Delivery with Promising Study
- Lexaria Bioscience says DehydraTECH-CBD study resulted in weight loss in rodents
- Lexaria Bioscience announces FDA clearance of Phase 1b hypertension trial
- Lexaria Bioscience prices $3.6M registered direct offering at $2.31 per share
- Lexaria Bioscience submits IND application to FDA for DehydraTECH-CBD trial
